Sacral Neuromodulation, also known as InterStim Therapy, is an innovative treatment option for individuals experiencing bladder and bowel control problems, such as urinary incontinence, overactive bladder, and fecal incontinence. At SHIFAA PAN African Hospitals, our urology experts offer Sacral Neuromodulation as a minimally invasive procedure to improve patients’ quality of life and restore pelvic floor function.

Understanding Sacral Neuromodulation:

Purpose and Importance:

• Sacral Neuromodulation aims to regulate nerve signals that control bladder and bowel function, helping manage symptoms such as urgency, frequency, incomplete emptying, and incontinence.
• The therapy is particularly beneficial for patients who have not responded well to conservative treatments like medications or behavioral therapies.

Procedure Overview:

Pre-procedure Evaluation:

• Patients undergo detailed assessments, including medical history reviews, physical examinations, urodynamic testing, and possibly imaging studies, to evaluate bladder and bowel function and identify specific issues.
• Candidacy for Sacral Neuromodulation is determined based on diagnostic findings, symptom severity, treatment history, and patient goals.

Implantation Process:

• Trial Stimulation: Before permanent implantation, a temporary electrode is placed near the sacral nerves through a minimally invasive procedure. Patients undergo a trial period to assess the therapy’s effectiveness in symptom improvement.
• Permanent Implantation: If the trial stimulation is successful, a permanent pulse generator (similar to a pacemaker) is implanted under the skin, typically in the buttock area. The device delivers mild electrical pulses to modulate nerve activity.

Post-Procedure Care and Recovery:

Device Programming and Adjustment:

• After implantation, the device is programmed to deliver optimal stimulation levels based on individual response and symptom management goals.
• Patients receive instructions on device use, activity restrictions, and potential adjustments or programming changes as needed.

Follow-up and Monitoring:

• Regular follow-up appointments are scheduled to assess treatment efficacy, adjust stimulation settings if necessary, and address any concerns or side effects.
• Patients are encouraged to keep a bladder or bowel diary to track symptoms and treatment outcomes, providing valuable information for ongoing management.

 

Who is a candidate for Sacral Neuromodulation?

Candidates include individuals with urinary or fecal incontinence, overactive bladder, pelvic floor dysfunction, or refractory symptoms not adequately managed with conservative treatments.

 

Is Sacral Neuromodulation reversible?

While the therapy is reversible, it is designed for long-term symptom management. Patients can undergo device removal if needed, but many experience sustained benefits with ongoing therapy.

 

What are the potential benefits of Sacral Neuromodulation?

Benefits may include improved bladder or bowel control, reduced urgency and frequency, decreased incontinence episodes, enhanced quality of life, and reduced reliance on medications.

 

Are there risks associated with Sacral Neuromodulation?

Risks may include surgical complications, device-related issues (such as lead migration or malfunction), infection, pain at implantation sites, or stimulation-related side effects like tingling or discomfort. Healthcare teams monitor patients closely to minimize risks.

 

Can patients resume normal activities after implantation?

Most patients can resume normal daily activities following recovery from implantation. Avoiding strenuous activities or specific movements that may impact the implant site is typically advised during the initial healing period.

 

Does insurance typically cover Sacral Neuromodulation therapy?

Insurance coverage for Sacral Neuromodulation varies by provider and policy. Patients should consult with their insurance companies and healthcare providers to understand coverage details, pre-authorization requirements, and potential out-of-pocket costs.